• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Lyra Therapeutics appoints new chief medical officer

July 5, 2022 By Sean Whooley

Lyra Therapeutics chief medical officer Richard Neiman

Lyra Therapeutics (Nasdaq:LYRA) announced today that it appointed Dr. Richard Nieman as its new chief medical officer (CMO). Nieman’s appointment as CMO of Lyra, which develops the XTreo — a platform for enabling precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — will be […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Personnel, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics, Personnel, Personnel Moves

Medtronic completes Intersect ENT acquisition

May 13, 2022 By Sean Whooley

Medtronic Intersect ENT

Medtronic (NYSE:MDT) announced that it completed its previously announced $1.1 billion acquisition of Intersect ENT (Nasdaq:XENT). Fridley, Minnesota-based Medtronic announced in August 2021 that it would acquire all outstanding shares of the Menlo Park, Calif.-based sinus implant maker for $28.25 per share in an all-cash transaction. As a result of the transaction, Medtronic acquires Intersect ENT’s Propel and Sinuva drug-eluting […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Otolaryngology Ear, Nose & Throat Tagged With: Intersect ENT Inc., Medtronic

ProMed Pharma begins preclinical testing of resorbable contraceptive implant

April 20, 2022 By Brian Buntz

ProMed

After receiving funding from the Bill & Melinda Gates Foundation, ProMed Pharma has begun preclinical evaluation of a novel fully resorbable contraceptive implant. The Plymouth, Minnesota–based company imagines that the contraceptive implants could ultimately find use in low- and middle-income (LMIC) settings. The novel implant potentially could offer women 18 months of contraception through the […]

Filed Under: Drug-Device Combinations, Implants, Women's Health Tagged With: Bill & Melinda Gates Foundation, contraceptive implants, levonorgestrel, ProMed Pharma

Ariste Medical co-founder sees great potential for drug-coated implants and orthopedics

April 18, 2022 By Jim Hammerand

Orange polypropylene mesh coated with antibiotics

It’s been more than a decade since Lisa Jennings launched not one but two companies in the Great Recession. In 2020, she sold CirQuest Labs to MLM Medical Labs, where Jennings serves as chief scientific officer and managing director of U.S. operations. More recently, her pre-commercial medtech development startup, Ariste Medical, won FDA 510(k) approval for […]

Filed Under: Drug-Device Combinations, Featured, Grafts, Implants, Materials Testing, Orthopedics, Pharmaceuticals, Research & Development, Stents, Uncategorized Tagged With: Ariste Medical, implantable devices

Senseonics announces first Eversense E3 CGM implant in U.S.

April 7, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring Tagged With: Ascensia Diabetes Care, Eversense, Senseonics

FDA clears antibiotic-embedded hernia mesh for fighting implant infections

April 6, 2022 By Jim Hammerand

Ariste Medical’s polypropylene hernia mesh

Ariste Medical recently won FDA 510(k) clearance for its drug-embedded, polypropylene hernia mesh to fight microbial colonization. The Salt Lake City-based drug-device developer said the patents and proprietary formulations behind the technology could prevent infection, inflammation or clotting associated with implants. Ariste’s synthetic mesh carries two antibiotics — minocycline and rifampin —  to prevent contamination […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants Tagged With: Ariste Medical, FDA

PAVmed completes first-in-human implantations of its intraosseous infusion system

March 17, 2022 By Sean Whooley

PAVmed PortIO

PAVmed (Nasdaq:PAVM) has successfully completed the first human implants of its PortIO intraosseous infusion system, the company said today. New York-based PAVmed designed its PortIO system with an implantable intraosseous vascular access device and insertion kit. Instead of a catheter located in a vein, the system has a short extension from the device inserted by […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Vascular Tagged With: PAVmed

Second Sight Medical, Nano Precision Medical merging to create therapeutic implant company

February 8, 2022 By Sean Whooley

Second Sight Medical Nano Precision Medical

Second Sight Medical Products (NSDQ:EYES) and Nano Precision Medical agreed to a merger deal that will focus on drug-device medical implants. The two companies entered into a definitive agreement under which privately held Nano Precision Medical (NPM) will merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM the surviving company […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals Tagged With: Nano Precision Medical, Second Sight

Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment

January 24, 2022 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (NSDQ:LYRA) announced today that it initiated the Phase 3 Enlighten I trial for its LYR-210 treatment. Watertown, Massachusetts-based Lyra’s Phase 3 Enlighten I clinical trial will evaluate LYR-210, delivered through Lyra’s proprietary XTreo drug-eluting implant, in adult, surgically naïve chronic rhinosinusitis (CRS) patients. The company designed LYR-210 for delivery in a brief, non-invasive, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Lyra Therapeutics

Ocular Therapeutix touts positive trial results of ophthalmic insert for dry eye disease

December 6, 2021 By Sean Whooley

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) announced today that it reported positive results from a Phase 2 trial of its dry eye disease treatment. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based Phase 2 clinical trial evaluated OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The randomized, double-masked, vehicle-controlled, multi-center trial evaluated two different formulations of […]

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Ocular Therapeutix

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 14
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS